Understanding and Managing Methotrexate Nephrotoxicity

Understanding and Managing Methotrexate Nephrotoxicity Brigitte C. Widemann, Peter C. Adamson Oncologist 2006; 11: 694-703 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in pediatric oncology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the clinical pharmacology of methotrexate and leucovorin rescue. Describe the current incidence and presentation of high-dose methotrexate-induced renal dysfunction. Select appropriate conventional, and consider investigational, treatment approaches to high-dose methotrexate-induced renal dysfunction. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: June 22, 2006 Most Recent Review: June 12, 2007* Most Recent Update: June 22, 2006 Date Credit Expires: June 22, 2008 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.